2.47
0.02 (0.82%)
| Penutupan Terdahulu | 2.45 |
| Buka | 2.40 |
| Jumlah Dagangan | 765,053 |
| Purata Dagangan (3B) | 1,994,303 |
| Modal Pasaran | 239,378,608 |
| Harga / Jualan (P/S) | 5.75 |
| Harga / Buku (P/B) | 1.53 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Keuntungan | -259.60% |
| Margin Operasi (TTM) | -402.93% |
| EPS Cair (TTM) | -1.48 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 138.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 32.99% |
| Nisbah Semasa (MRQ) | 5.70 |
| Aliran Tunai Operasi (OCF TTM) | -80.32 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -53.06 M |
| Pulangan Atas Aset (ROA TTM) | -20.30% |
| Pulangan Atas Ekuiti (ROE TTM) | -45.55% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | C4 Therapeutics, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 1.25 |
|
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 9.79% |
| % Dimiliki oleh Institusi | 91.87% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 10.00 (Barclays, 304.86%) | Beli |
| 10.00 (Wells Fargo, 304.86%) | Beli | |
| Median | 10.00 (304.86%) | |
| Rendah | 6.00 (Stephens & Co., 142.92%) | Beli |
| Purata | 8.67 (251.01%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 2.60 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Barclays | 23 Sep 2025 | 10.00 (304.86%) | Beli | 2.59 |
| 17 Sep 2025 | 8.00 (223.89%) | Beli | 3.38 | |
| Wells Fargo | 23 Sep 2025 | 10.00 (304.86%) | Beli | 2.59 |
| Stephens & Co. | 22 Sep 2025 | 6.00 (142.91%) | Beli | 2.61 |
| 15 Sep 2025 | 6.00 (142.91%) | Beli | 3.57 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |